

| set of samples | samples | clinical status | age/sex | paired with | supplier |
|----------------|-------------|---|---------|-------------|-------------------|
| colon N | colon N1 | Adjacent normal | 40/M | colon T1 | Life Technologies |
| | colon N2 | Adjacent normal | 62/F | colon T2 | Clinisciences |
| | colon N3 | Adjacent normal | 68/F | colon T3 | Clinisciences |
| | colon N4 | Adjacent normal | 62/F | colon T4 | Clinisciences |
| colon T | colon T1 | Adenocarcinoma | 40/M | colon N1 | Life Technologies |
| | colon T2 | Adenocarcinoma, mucinous moderately differentiated | 62/F | colon N2 | Clinisciences |
| | colon T3 | Adenocarcinoma, mucinous poorly differentiated | 68/F | colon N3 | Clinisciences |
| | colon T4 | Adenocarcinoma, moderately differentiated | 62/F | colon N4 | Clinisciences |
| lung N | lung N1 | Adjacent normal | 72/M | lung T1 | Life Technologies |
| | lung N2 | Adjacent normal | 58/M | lung T2 | CRB Nancy |
| | lung N3 | Adjacent normal | 67/M | lung T3 | CRB Nancy |
| | lung N4 | Adjacent normal | 53/M | lung T4 | CRB Nancy |
| | lung N5 | Adjacent normal | 56/M | lung T5 | CRB Nancy |
| | lung N6 | Adjacent normal | 58/M | lung T6 | CRB Nancy |
| | lung N7 | Adjacent normal | 52/M | lung T7 | CRB Nancy |
| | lung N8 | Adjacent normal | 47/M | lung T8 | CRB Nancy |
| | lung N9 | Adjacent normal | 78/M | lung T9 | CRB Nancy |
| | lung N10 | Adjacent normal | 63/M | lung T10 | CRB Nancy |
| lung T | lung T1 | Squamous cell carcinoma | 72/M | lung N1 | Life Technologies |
| | lung T2 | Epidermoid, T1N0 | 58/M | lung N2 | CRB Nancy |
| | lung T3 | Epidermoid, T1N0 | 67/M | lung N3 | CRB Nancy |
| | lung T4 | Epidermoid, T2N0 | 53/M | lung N4 | CRB Nancy |
| | lung T5 | Epidermoid, T1N0 | 56/M | lung N5 | CRB Nancy |
| | lung T6 | Epidermoid, T2N1 | 58/M | lung N6 | CRB Nancy |
| | lung T7 | Epidermoid, T2N1 | 52/M | lung N7 | CRB Nancy |
| | lung T8 | Epidermoid, T2N0 | 47/M | lung N8 | CRB Nancy |
| | lung T9 | Epidermoid, T1N0 | 78/M | lung N9 | CRB Nancy |
| | lung T10 | Epidermoid, T2N1 | 63/M | lung N10 | CRB Nancy |
| breast N | breast N1 | Adjacent normal | 56/F | breast T1 | Clinisciences |
| | breast N2 | Adjacent normal | 41/F | breast T2 | Clinisciences |
| | breast N3 | Adjacent normal | 63/F | breast T3 | Clinisciences |
| | breast N4 | Adjacent normal | 50/F | breast T4 | Clinisciences |
| | breast N5 | Adjacent normal | 50/F | breast T5 | Clinisciences |
| | breast N6 | Adjacent normal | 47/F | breast T6 | Clinisciences |
| | breast N7 | Adjacent normal | 53/F | breast T7 | Clinisciences |
| | breast N8 | Adjacent normal | 58/F | breast T8 | Clinisciences |
| breast T | breast T1 | Invasive ductal carcinoma | 56/F | breast N1 | Clinisciences |
| | breast T2 | Invasive ductal carcinoma | 41/F | breast N2 | Clinisciences |
| | breast T3 | Invasive ductal carcinoma | 63/F | breast N3 | Clinisciences |
| | breast T4 | Invasive ductal carcinoma | 50/F | breast N4 | Clinisciences |
| | breast T5 | Invasive ductal carcinoma | 50/F | breast N5 | Clinisciences |
| | breast T6 | Invasive ductal carcinoma | 47/F | breast N6 | Clinisciences |
| | breast T7 | Invasive lobular carcinoma, moderately differentiated | 53/F | breast N7 | Clinisciences |
| | breast T8 | Invasive ductal carcinoma, poorly differentiated | 58/F | breast N8 | Clinisciences |
| ovary N | ovary N1 | Adjacent normal | 32/F | ovary T1 | Life Technologies |
| | ovary N2 | Adjacent normal | 71/F | ovary T2 | Clinisciences |
| | ovary N3 | Adjacent normal | 20/F | ovary T3 | Clinisciences |
| | ovary N4 | Adjacent normal | 40/F | ovary T4 | Clinisciences |
| ovary T | ovary T1 | Papillary cystadeno carcinoma | 32/F | ovary N1 | Life Technologies |
| | ovary T2 | Right ovary endometrioid carcinoma, moderately differentiated | 71/F | ovary N2 | Clinisciences |
| | ovary T3 | Yolk sac cystadenoma | 20/F | ovary N3 | Clinisciences |
| | ovary T4 | Mucinous cystodeno carcinoma | 40/F | ovary N4 | Clinisciences |
| prostate N | prostate N1 | Adjacent normal | 82/M | prostate T1 | Clinisciences |
| | prostate N2 | Adjacent normal | 53/M | prostate T2 | Life Technologies |
| | prostate N3 | Adjacent normal | 73/M | prostate T3 | Life Technologies |
| | prostate N4 | Adjacent normal | 56/M | prostate T4 | CH Lyon Sud |
| | prostate N5 | Adjacent normal | 63/M | prostate T5 | CH Lyon Sud |
| | prostate N6 | Adjacent normal | 73/M | prostate T6 | CH Lyon Sud |
| | prostate N7 | Adjacent normal | 66/M | prostate T7 | CH Lyon Sud |
| | prostate N8 | Adjacent normal | 68/M | prostate T8 | CH Lyon Sud |
| prostate T | prostate T1 | Prostate cancer | 82/M | prostate N1 | Clinisciences |
| | prostate T2 | Adenocarcinoma, well differentiated | 53/M | prostate N2 | Life Technologies |
| | prostate T3 | Adenocarcinoma, well to poorly differentiated Gleason 7 | 73/M | prostate N3 | Life Technologies |
| | prostate T4 | Prostate adenocarcinoma, pT3bN1 Gleason 7 | 56/M | prostate N4 | CH Lyon Sud |
| | prostate T5 | Prostate adenocarcinoma, pT2cN0 Gleason 7 | 63/M | prostate N5 | CH Lyon Sud |
| | prostate T6 | Prostate adenocarcinoma, pT2cN0 Gleason 6 | 73/M | prostate N6 | CH Lyon Sud |
| | prostate T7 | Prostate adenocarcinoma, pT2cN0 Gleason 7 | 66/M | prostate N7 | CH Lyon Sud |
| | prostate T8 | Prostate adenocarcinoma, pT2cN0 Gleason 7 | 68/M | prostate N8 | CH Lyon Sud |
| testis N | testis N1 | Adjacent normal | 33/M | testis T1 | Life Technologies |
| | testis N2 * | Adjacent normal | 26/M | testis T2 | Life Technologies |
| | testis N3 * | Adjacent normal | 30/M | testis T3 | Clinisciences |
| testis T | testis T1 | Seminoma | 33/M | testis N1 | Life Technologies |
| | testis T2 * | Seminoma, T3N1 | 26/M | testis N2 | Life Technologies |
| | testis T3 * | Seminoma | 30/M | testis N3 | Clinisciences |
| uterus N | uterus N1 | Adjacent normal | 47/F | uterus T1 | Life Technologies |
| | uterus N2 | Adjacent normal | 49/F | uterus T2 | Clinisciences |
| | uterus N3 | Adjacent normal | 55/F | uterus T3 | Clinisciences |
| | uterus N4 | Adjacent normal | 41/F | uterus T4 | Clinisciences |
| uterus T | uterus T1 | Choriocarcinoma | 47/F | uterus N1 | Life Technologies |
| | uterus T2 | Adenocarcinoma, poorly differentiated | 49/F | uterus N2 | Clinisciences |
| | uterus T3 | Adenocarcinoma, poorly differentiated | 55/F | uterus N3 | Clinisciences |
| | uterus T4 | Endometrioid adenocarcinoma | 41/F | uterus N4 | Clinisciences |
| placenta | placenta N1 | Normal term | 30/F | no | Life Technologies |